Retatrutide
Tested in peopleIt has been tested in people, but it is not an approved medicine. The studies are usually small.
Also called LY3437943 / Triple G / GGG tri-agonist
Hits three different hormone targets at once for weight loss. In late-stage human trials, not yet approved.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Still an investigational drug in clinical trials. Not approved and not legal to compound.
Official status: Not on the 503A bulks list. Checked 2026-08-04.
Lab suppliers we list: 4
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
In human trials
See source wording
under the skin · weekly
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightPHASE2 · NCT07467447
“Retatrutide (LY3437943) 1 mg once weekly (no escalation).”
In animal studies
10 mg
mice ·
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.American journal of physiology. Gastrointestinal and liver physiology · 2025
“C57BL/6N mice were subjected to a single fructose binge (10 mg/g body wt), or a new 31-day mouse model of diet-induced steatohepatitis using a Western diet, fructose, and sucrose in the drinking water, and a final fructose binge with or without retatrutide.”
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Study in people
Lancet (London, England) · 2026
- Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide
Study in people
Journal not recorded · 2026
- Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Study in people
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Study in people
Obesity pillars · 2025
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Study in people
Diabetes, obesity & metabolism · 2025
- Retatrutide showing promise in obesity (and type 2 diabetes).
Study in people
Expert opinion on investigational drugs · 2023
- Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Animal study, rats or mice
Behavioural brain research · 2026
- Retatrutide Treatment in Streptozotocin-Induced Diabetic Rats: Renal Inflammatory Cytokines, HIF‑1α Signalling, and Histopathological Injury Profile
Animal study, rats or mice
Journal not recorded · 2026
- Retatrutide effects on diabetic rats' cognition.
Animal study, rats or mice
Lab animal · 2026
- Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
Animal study, rats or mice
Diabetology & metabolic syndrome · 2026
- Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
Animal study, rats or mice
Obesity (Silver Spring, Md.) · 2026
- Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Male Diabetic Rats
Animal study, rats or mice
Journal not recorded · 2026
- GIPR:GCGR co-agonism restores normal weight in obese rodents.
Animal study, rats or mice
Molecular metabolism · 2026
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
Animal study, rats or mice
International journal of obesity (2005) · 2026
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
Animal study, rats or mice
npj metabolic health and disease · 2025
- Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
Animal study, rats or mice
American journal of physiology. Gastrointestinal and liver physiology · 2025
- Retatrutide in type 2 diabetes mellitus and obesity: an overview.
Expert review of clinical pharmacology · 2026
- The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Clinical pharmacology in drug development · 2026
- Inotropic effects of retatrutide in isolated human atrial preparations.
Naunyn-Schmiedeberg's archives of pharmacology · 2026
- Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
European journal of internal medicine · 2026
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
Organic letters · 2026
- Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism · 2026
- Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Cardiology in review · 2026
- Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
BMJ (Clinical research ed.) · 2026
- Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
BMJ (Clinical research ed.) · 2026
- Retatrutide.
Clinical diabetes : a publication of the American Diabetes Association · 2024
- Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.
Cell discovery · 2024
- Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.
Health science reports · 2024
- Incretin-based therapies for the treatment of obesity-related diseases.
npj metabolic health and disease · 2024
- Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Expert opinion on investigational drugs · 2023
- GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Review of earlier work
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
Review of earlier work
The Indian journal of medical research · 2026
- Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Review of earlier work
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.
Review of earlier work
Clinical and molecular hepatology · 2026
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Review of earlier work
Endocrinology, diabetes & metabolism · 2026
- Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
Review of earlier work
Aesthetic surgery journal · 2026
- Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic Disorders
Review of earlier work
Journal not recorded · 2026
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
Review of earlier work
Proceedings (Baylor University. Medical Center) · 2025
- Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
Review of earlier work
Maedica · 2025
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
Review of earlier work
Expert review of clinical pharmacology · 2025
- Triple Agonism Based Therapies for Obesity.
Review of earlier work
Current cardiovascular risk reports · 2025
- The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
Review of earlier work
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
Review of earlier work
Indian journal of endocrinology and metabolism · 2024